Jefferies Lifts PT on Sportradar Group (SRAD) Stock, Maintains Buy
A customer data analyst working at a computer, surrounded by monitors displaying live sports data.
IMG ARENA's portfolio is expected to enhance Sportradar Group AG (NASDAQ:SRAD)'s content and product offering and further strengthen the position as a leading content provider in the most bet-upon global sports, such as tennis, soccer, and basketball. Notably, the addition of these betting rights to its content portfolio increases Sportradar Group AG (NASDAQ:SRAD)'s depth and breadth in critical global sports, expanding the content distribution and fueling product development.
Thanks to the highly scalable technology platform and extensive client network, Sportradar Group AG (NASDAQ:SRAD) is expected to seamlessly integrate and monetize the rights, fueling incremental value. The acquisition is expected to further accelerate Sportradar Group AG (NASDAQ:SRAD)'s strong revenue, adjusted EBITDA, and cash flow growth.
Sportradar Group AG (NASDAQ:SRAD) offers sports data services for the sports betting and media industries. It provides betting technology and solutions, such as betting and gaming content, real-time sports data points, among other offerings.
While we acknowledge the potential of SRAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Heartflow raises $316.7 million in US IPO as medtech listings attempt comeback
By Ateev Bhandari and Pritam Biswas (Reuters) -Medical technology firm Heartflow said on Thursday it had raised $316.7 million in its U.S. initial public offering, setting the stage for its Nasdaq debut in another test of investor appetite for medical tech companies. The Mountain View, California-based company sold 16.67 million shares at $19 each, compared with a targeted range of $17 to $18 apiece. It upsized its offering and raised the proposed range earlier this week reflecting strong demand. The IPO valued the company at $1.54 billion. U.S. IPOs have picked up pace in a much-awaited recovery, as solid tech earnings and progress on trade deals have helped restore investor confidence. Strong recent debuts mark a reversal from early April, when uncertainty around U.S. President Donald Trump's tariffs paused dealmaking. Heartflow's stock will begin trading on the Nasdaq on Friday under the "HTFL" ticker symbol. The closing of the offering is expected on August 11. J.P. Morgan, Morgan Stanley and Piper Sandler are the lead underwriters for the offering. Following software firm Figma's blowout debut last week, analysts expect companies with a compelling growth story to be welcomed by the public markets. "We expect Heartflow to be well received at launch, especially following Figma's breakout success, which has helped reset sentiment toward high-growth names," IPOX CEO Josef Schuster said. Bain Capital-backed Heartflow leverages AI to create 3D models of the heart via a single specialized scan, improving detection and treatment of coronary artery disease (CAD). As AI gains widespread acceptance, companies embedding it into workflows for meaningful use cases are catching investor attention, with the technology powering gains across various Big Tech businesses. Heartflow's revenue grew 39% for the quarter ended March 31 from a year earlier. Its platform to detect CAD was used in 132,000 patients in 2024. Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
Trump Wildly Claims Wall Street Journal And China Are In Cahoots Amid Epstein Lawsuit
President Donald Trump alleged in a bizarre rant that The Wall Street Journal wants to see China 'WIN, BABY, WIN' on Thursday. 'The reason that The Wall Street Journal Editorial Board is always negative on 'TRUMP,' and the Hundreds of Billions of Dollars we're bringing into our Country through Tariffs, numbers that the U.S.A. has never seen before, is because they are China centric or, at a minimum, Globalists, and they would rather see China and the World, for reasons unknown, 'WIN, BABY, WIN,' the POTUS wrote in a Truth Social post. Trump then insisted that if 'the United States were not able to charge Tariffs to other Countries, it would be Economically defenseless and, of no further force or effect. The only thing that can destroy our Country are Crooked, Radical Left Judges, of which there are many!' The president has faced scrutiny over his sweeping global tariffs, which went into effect Thursday, subsequently raising the prices of household goods for Americans. The tariffs are projected to affect imports from more than 60 countries. The WSJ — which has grilled the president's efforts during his second term in office — and Trump have been embroiled in an ongoing feud. The dispute ignited further after the outlet published a report about an alleged, racy birthday cardthat Trump sent to convicted sex offender and disgraced financier Jeffrey Epstein in 2003. The letter was said to contain a drawing of a naked woman and a strange message about secrets, according to the WSJ. Trump, who is suing the WSJ over its report on the letter, has denied writing the letter. 'I never wrote a picture in my life. I don't draw pictures of women,' he told the Journal. 'It's not my language. It's not my words.' The president added: 'I'm gonna sue The Wall Street Journal just like I sued everyone else.' Trump further slammed the WSJ over their report in a separate Truth Social post, calling the article a 'false, malicious, and defamatory story.' Related... Trump Fires Back At Reporters Over 'Bulls**t' Epstein Question Trump Lashes Out At 'Racist Sleazebag' Charlamagne Tha God After Epstein-MAGA Comment Trump's Sleight-Of-Hand On The Jeffrey Epstein Scandal
Yahoo
21 minutes ago
- Yahoo
Texans safety C.J. Gardner-Johnson did not tear ACL in right knee, as originally feared
Houston Texans safety C.J. Gardner-Johnson was feared to have torn the anterior cruciate ligament in his right knee. However, subsequent reports followed up to say that Gardner-Johnson did not tear his ACL and will undergo further tests to determine the severity of the injury. [Join or create a Yahoo Fantasy Football league for the 2025 NFL season] According to KPRC2's Aaron Wilson, Gardner-Johnson was defending wide receiver John Metchie III during a scrimmage in West Virginia when the injury occurred. As he went to make a tackle, he went to the ground and clutched his leg. Texans players took a knee near Gardner-Johnson as silence took over the field. The NFL's interceptions leader in 2022 was unable to put weight on his leg as he was helped onto a cart to be taken to be evaluated. "It's heartbreaking when you see a guy go down on a field like that and doesn't get up quickly" Texans head coach Demeco Ryans said afterward. "I'm always nervous as a head coach anytime I see anybody hit the ground, it's tough to watch." Gardner-Johnson, 27, spent last season with the Philadelphia Eagles where he helped them win Super Bowl LIX. He had 59 tackles and six interceptions in 2024 and has picked off 13 passes over the past three seasons. After one season back with the Eagles, Gardner-Johnson was dealt in March to Houston in a trade that sent guard Kenyon Green to Philadelphia. The Texans had plans for him to replace Eric Murray in their secondary after Murray signed with the Jacksonville Jaguars. Gardner-Johnson began his NFL career with three seasons with the New Orleans Saints. He joined the Eagles 2022 before moving on to the Detroit Lions in 2023. After only three games with the Lions, he suffered a torn pectoral and missed the rest of the season. That offseason, he signed a three-year deal to return to Philadelphia.
